Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02639676 · ClinicalTrials.gov registry record
Anti-Angiogenic Preeclampsia Milieu Impairs Infant Lung and Vascular Development
A clinical trial, sponsored by Indiana University.
- Completed
- Registry status
- 292
- Enrollment target
NCT02639676: Completed study, sponsored by Indiana University.
NCT02639676 is a clinical trial that has completed, run by Indiana University. The registered enrollment target is 292 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02639676 has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- 292 participants
- Enrollment target
Study Summary
Pregnant mothers who develop high blood pressure and other vascular problems (preeclampsia) deliver babies with increased neonatal health problems, which include lung disease and vascular complications, later in life. Investigators will evaluate whether infants of mothers with preeclampsia have evidence for impaired development of the lungs and blood vessels.
Interventions
- OTHER Diffusion Lung Capacity (DLCO), Vascular Challenge, Video Imaging, Specimen Collections
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 292 participants |
| Start Date | 2016-02-11 |
| Est. Completion | 2020-11-17 |
What the finished NCT02639676 record still lists
NCT02639676 is an observational study that tracks outcomes without assigning an intervention. The registered 292 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Diffusion Lung Capacity (DLCO), Vascular Challenge, Video Imaging, Specimen Collections is the first listed.
NCT02639676 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02639676 about?
NCT02639676 is a clinical study titled "Anti-Angiogenic Preeclampsia Milieu Impairs Infant Lung and Vascular Development". Pregnant mothers who develop high blood pressure and other vascular problems (preeclampsia) deliver babies with increased neonatal health problems, which include lung disease and vascular complications, later in life. Investigators will evaluate whether infants of mothers with preeclampsia have evid...
What is the current status of trial NCT02639676?
This trial is currently completed. The enrollment target is 292 participants. The study started on 2016-02-11. Estimated completion is 2020-11-17.
What interventions are being tested in trial NCT02639676?
The interventions under investigation include: Diffusion Lung Capacity (DLCO), Vascular Challenge, Video Imaging, Specimen Collections (OTHER).
Who is sponsoring clinical trial NCT02639676?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04429542 · 292 participants · Phase 1
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- NCT05406622 · 292 participants · NA
MOTIV BTK Randomized Controlled Trial
- NCT05757102 · 292 participants · Phase 3
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
- NCT06569667 · 292 participants · NA
Using AI and Peer Coaching to Address Racial Disparities Among People Who Use Opioids
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI